TrumpRx expands to everyday medicines and generics

TrumpRx.gov, the federal website that launched in February 2026 with discounted prices on branded drugs including Ozempic, Wegovy and Zepbound, has widened its scope to include retail generic medicines, according to the site itself and White House materials ^[1][2]. The expansion moves TrumpRx from a showcase for most-favored-nation (MFN) pricing deals into what the administration is now framing as a broader tool for comparing drug prices ^[2].

When TrumpRx.gov launched on February 5, 2026, it featured 40 branded drugs from the first five manufacturers to sign MFN deals with the administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer ^[1]. Among the highlighted savings, the monthly price of Ozempic was set to fall from $1,028 to an average of $350, and as low as $199 depending on dosage ^[1]. Injectable Wegovy was listed at a similar average of $350 and as low as $199, while the Wegovy pill dropped from $1,349 to as low as $149 ^[1]. Zepbound, Eli Lilly's tirzepatide injection, was priced at an average of $346 and as low as $299, down from $1,088 ^[1].

The site now displays a running total of "$700,000,000+" saved for Americans and advertises that it includes "hundreds of generics," a tagline that did not appear in the original February launch materials ^[2]. The homepage still uses branded drugs, including Wegovy, Ozempic and Zepbound, as its lead price examples, but it now also promotes a broader search and browse function for medications generally, rather than only the 40 branded products tied to manufacturer MFN agreements ^[2].

The site's public FAQ list includes new questions aimed at pharmacies and prescribers about generic drugs, such as how retail pharmacy offers for generics are selected for the site and how pharmacies can update their generic pricing information ^[2]. The site does not publish the answers to those questions in the material reviewed, so it is not yet known exactly how generic prices are sourced, verified or updated, or which retail pharmacies are participating ^[2].

Why it matters for patients

For patients on GLP-1 medications, the core numbers posted for Ozempic, Wegovy and Zepbound have not changed from the February rollout: those prices remain tied to manufacturer MFN deals and require a valid prescription, with savings delivered through coupons or manufacturer-run channels integrated into the site ^[1]. The new generics feature is a separate function, aimed at people comparing prices on medicines outside the 40 branded drugs covered by the original deals ^[2].

Because the sources do not specify which generic drugs, pharmacies or price sources are involved, patients cannot yet know whether a given generic medication they take will show up on the site, or how current the listed generic prices will be ^[2]. The site's own FAQ, which addresses questions like whether TrumpRx prices can be combined with insurance and how prescriptions are routed to pharmacies, is listed with unanswered entries in the material available, so those mechanics remain unclear ^[2].

What happens next

The White House has said additional drugs from other manufacturers that sign MFN deals will be added to TrumpRx.gov "in the coming months," a process that began before this generics expansion ^[1]. The administration's related announcements referenced in White House materials include a deal with Regeneron dated April 23, 2026, and a further announcement of deals with nine additional manufacturers dated August 31, 2026, though the content of those specific announcements was not part of the material reviewed here ^[1].